Clinical Trial Update: LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LDE225 (sonidegib) for stage II-III estrogen receptor- and HER2-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• LDE225 (sonidegib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Neoplasms | Phase 2 | Status: WITHDRAWN